Emerging Metabolic Therapies in Pulmonary Arterial Hypertension.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28375184)

Published in J Clin Med on April 04, 2017

Authors

Lloyd D Harvey1, Stephen Y Chan2

Author Affiliations

1: Medical Scientist Training Program, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. lloydharvey@pitt.edu.
2: Division of Cardiology, Center for Pulmonary Vascular Biology and Medicine, Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute, University of Pittsburgh School of Medicine and University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA. chansy@pitt.edu.

Articles cited by this

(truncated to the top 100)

Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82

On the origin of cancer cells. Science (1956) 49.55

Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21

Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls. Genes Dev (1999) 13.24

Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med (1991) 13.21

Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol (2009) 12.05

Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. Cancer Cell (2011) 11.44

ATP-citrate lyase links cellular metabolism to histone acetylation. Science (2009) 8.82

A class of membrane proteins shaping the tubular endoplasmic reticulum. Cell (2006) 8.53

ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol (2009) 7.94

Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem (1997) 7.67

Disruption of fusion results in mitochondrial heterogeneity and dysfunction. J Biol Chem (2005) 7.30

Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu Rev Cell Dev Biol (2011) 7.07

Treatment of pulmonary arterial hypertension. N Engl J Med (2004) 6.88

Iron-sulfur clusters: nature's modular, multipurpose structures. Science (1997) 6.78

Mitochondrial fusion and fission in cell life and death. Nat Rev Mol Cell Biol (2010) 6.58

Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem (2007) 5.95

Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood (2004) 5.71

Two to tango: regulation of Mammalian iron metabolism. Cell (2010) 5.45

The role of iron regulatory proteins in mammalian iron homeostasis and disease. Nat Chem Biol (2006) 5.33

Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability. Proc Natl Acad Sci U S A (2011) 5.24

Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem (1996) 5.15

Oxygen sensing, homeostasis, and disease. N Engl J Med (2011) 5.03

Acute oxygen-sensing mechanisms. N Engl J Med (2005) 4.80

Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep (2007) 4.73

The impact of the unfolded protein response on human disease. J Cell Biol (2012) 4.36

Affinity-driven peptide selection of an NFAT inhibitor more selective than cyclosporin A. Science (1999) 4.20

Impaired physiological responses to chronic hypoxia in mice partially deficient for hypoxia-inducible factor 1alpha. J Clin Invest (1999) 4.00

Prognostic value of right ventricular mass, volume, and function in idiopathic pulmonary arterial hypertension. Eur Heart J (2007) 3.87

Cyclic AMP-dependent protein kinase phosphorylation of Drp1 regulates its GTPase activity and mitochondrial morphology. J Biol Chem (2007) 3.86

The ancient drug salicylate directly activates AMP-activated protein kinase. Science (2012) 3.77

Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med (1995) 3.70

The mitochondrion in apoptosis: how Pandora's box opens. Nat Rev Mol Cell Biol (2001) 3.66

The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium (2003) 3.38

Cell-permeating alpha-ketoglutarate derivatives alleviate pseudohypoxia in succinate dehydrogenase-deficient cells. Mol Cell Biol (2007) 3.33

MicroRNA-210 controls mitochondrial metabolism during hypoxia by repressing the iron-sulfur cluster assembly proteins ISCU1/2. Cell Metab (2009) 3.30

Genome-wide association of hypoxia-inducible factor (HIF)-1alpha and HIF-2alpha DNA binding with expression profiling of hypoxia-inducible transcripts. J Biol Chem (2009) 3.23

An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation (2006) 3.21

Structural studies on 2-oxoglutarate oxygenases and related double-stranded beta-helix fold proteins. J Inorg Biochem (2006) 3.08

Iron-sulfur cluster biogenesis and human disease. Trends Genet (2008) 3.03

Multifaceted roles of glycolytic enzymes. Trends Biochem Sci (2005) 3.01

Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med (1951) 3.00

Clinical characteristics of pulmonary hypertension in patients with heart failure and preserved ejection fraction. Circ Heart Fail (2011) 2.92

The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res (2000) 2.89

Structure of dual function iron regulatory protein 1 complexed with ferritin IRE-RNA. Science (2006) 2.88

Basic science of pulmonary arterial hypertension for clinicians: new concepts and experimental therapies. Circulation (2010) 2.85

Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A (2004) 2.79

Chronic pulmonary artery pressure elevation is insufficient to explain right heart failure. Circulation (2009) 2.73

Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Annu Rev Physiol (1974) 2.71

An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest (2008) 2.71

SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction. Circulation (2016) 2.71

Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med (2012) 2.68

Insulin resistance, hyperlipidemia, and hypertension in mice lacking endothelial nitric oxide synthase. Circulation (2001) 2.64

Activation of glycogen synthase kinase 3beta disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity. Cancer Res (2005) 2.64

Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation (2012) 2.54

Uncoupling proteins 2 and 3 are fundamental for mitochondrial Ca2+ uniport. Nat Cell Biol (2007) 2.46

Oxygen homeostasis. Wiley Interdiscip Rev Syst Biol Med (2010) 2.45

Alterations of cellular bioenergetics in pulmonary artery endothelial cells. Proc Natl Acad Sci U S A (2007) 2.44

Hypoxic pulmonary vasoconstriction. J Appl Physiol (1985) (2005) 2.38

Pathology of pulmonary hypertension. Clin Chest Med (2007) 2.34

Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol (2001) 2.24

Comparative metabolic flux profiling of melanoma cell lines: beyond the Warburg effect. J Biol Chem (2011) 2.24

Flirting in little space: the ER/mitochondria Ca2+ liaison. Sci STKE (2004) 2.22

Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc Res (1997) 2.21

MicroRNA-210: a unique and pleiotropic hypoxamir. Cell Cycle (2010) 2.18

Epigenetic attenuation of mitochondrial superoxide dismutase 2 in pulmonary arterial hypertension: a basis for excessive cell proliferation and a new therapeutic target. Circulation (2010) 2.06

Diversity in mitochondrial function explains differences in vascular oxygen sensing. Circ Res (2002) 2.06

Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res (2004) 2.06

An Essential Role of the Mitochondrial Electron Transport Chain in Cell Proliferation Is to Enable Aspartate Synthesis. Cell (2015) 2.03

Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther (2014) 2.03

Heterozygous deficiency of hypoxia-inducible factor-2alpha protects mice against pulmonary hypertension and right ventricular dysfunction during prolonged hypoxia. J Clin Invest (2003) 2.00

Inflammation in pulmonary arterial hypertension. Chest (2012) 1.99

The role of Nogo and the mitochondria-endoplasmic reticulum unit in pulmonary hypertension. Sci Transl Med (2011) 1.95

The inhibition of pyruvate dehydrogenase kinase improves impaired cardiac function and electrical remodeling in two models of right ventricular hypertrophy: resuscitating the hibernating right ventricle. J Mol Med (Berl) (2009) 1.94

The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A (2007) 1.93

In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab (2013) 1.93

Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc Natl Acad Sci U S A (1998) 1.92

Supporting Aspartate Biosynthesis Is an Essential Function of Respiration in Proliferating Cells. Cell (2015) 1.90

Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Invest (2008) 1.89

Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med (2003) 1.85

Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation (2002) 1.82

Dynamin-related protein 1-mediated mitochondrial mitotic fission permits hyperproliferation of vascular smooth muscle cells and offers a novel therapeutic target in pulmonary hypertension. Circ Res (2012) 1.81

Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation (1998) 1.80

Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med (2009) 1.77

Iron homeostasis and pulmonary hypertension: iron deficiency leads to pulmonary vascular remodeling in the rat. Circ Res (2015) 1.74

Restoring endoplasmic reticulum function by chemical chaperones: an emerging therapeutic approach for metabolic diseases. Diabetes Obes Metab (2010) 1.69

HIF and the lung: role of hypoxia-inducible factors in pulmonary development and disease. Am J Respir Crit Care Med (2011) 1.68

FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest (2013) 1.65

Increased [18F]fluorodeoxyglucose accumulation in right ventricular free wall in patients with pulmonary hypertension and the effect of epoprostenol. J Am Coll Cardiol (2005) 1.60

Disruption of PPARγ/β-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest (2011) 1.60

Inhibitors of permeability transition interfere with the disruption of the mitochondrial transmembrane potential during apoptosis. FEBS Lett (1996) 1.58

A fatal mitochondrial disease is associated with defective NFU1 function in the maturation of a subset of mitochondrial Fe-S proteins. Am J Hum Genet (2011) 1.57

A serine protease inhibitor prevents endoplasmic reticulum stress-induced cleavage but not transport of the membrane-bound transcription factor ATF6. J Biol Chem (2003) 1.57

In vivo gene transfer of the O2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation (2003) 1.54

Revisiting the TCA cycle: signaling to tumor formation. Trends Mol Med (2011) 1.51

Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol (2011) 1.48

Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol (2007) 1.47

Effect of altered redox states on expression and DNA-binding activity of hypoxia-inducible factor 1. Biochem Biophys Res Commun (1995) 1.47

Tie2-mediated loss of peroxisome proliferator-activated receptor-gamma in mice causes PDGF receptor-beta-dependent pulmonary arterial muscularization. Am J Physiol Lung Cell Mol Physiol (2009) 1.47

A unique pathway of cardiac myocyte death caused by hypoxia-acidosis. J Exp Biol (2004) 1.44